Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 72

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 72
---
, it could impose a substantial cost upon us and divert the resources
and attention of our management from our business.

| 32 |

Our Common Stock has often been thinly traded, so investors may be unable to sell at or near ask prices or at all if investors need to sell shares to raise money or otherwise desire to liquidate their shares.

To date, there have been many days on which limited
trading of our Common Stock took place. We cannot predict the extent to which investors’ interests will lead to an active trading
market for our Common Stock or whether the market price of our Common Stock will be volatile. If an active trading market does not develop,
investors may have difficulty selling our Common Stock. We are likely to be too small to attract the interest of many brokerage firms
and analysts. We cannot give investors any assurance that an active public trading market for our Common Stock will develop or be sustained.
The market price of our Common Stock could be subject to wide fluctuations in response to quarterly variations in our revenues and operating
expenses, announcements of new products or services by us, significant sales of our Common Stock, including “short” sales,
the operating and stock price performance of other companies that investors may deem comparable to us, and news reports relating to trends
in our markets or general economic conditions.

An investment in our Company may involve tax implications, and you are encouraged to consult your own advisors as neither we nor any related party is offering any tax assurances or guidance regarding our Company or your investment.

An investment in our Company generally, involves complex
federal, state, and local income tax considerations. Neither the Internal Revenue Service nor any state or local taxing authority has
reviewed the transactions described herein and may take different positions than the ones contemplated by management. You are strongly
urged to consult your own tax and other advisors prior to investing, as neither we nor any of our officers, directors, or related parties
can offer tax or similar advice, nor are any such persons making any representations and warranties regarding such matters.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

Under Section 382 of the Internal Revenue Code of
1986, as amended, if a corporation undergoes an “ownership change” (generally defined as a greater than 50% change (by value)
in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards
and other pre-change tax attributes (such as research tax